Portal de Periódicos da CAPES

Genetic variants are identified to increase risk of COVID-19 related mortality from UK Biobank data

2021; BioMed Central; Volume: 15; Issue: 1 Linguagem: Inglês

10.1186/s40246-021-00306-7

1479-7364

Jianchang Hu, Li Cai, Shiying Wang, Ting Li, Heping Zhang,

Genetic Associations and Epidemiology

Abstract Background The severity of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly heterogeneous. Studies have reported that males and some ethnic groups are at increased risk of death from COVID-19, which implies that individual risk of death might be influenced by host genetic factors. Methods In this project, we consider the mortality as the trait of interest and perform a genome-wide association study (GWAS) of data for 1778 infected cases (445 deaths, 25.03%) distributed by the UK Biobank. Traditional GWAS fails to identify any genome-wide significant genetic variants from this dataset. To enhance the power of GWAS and account for possible multi-loci interactions, we adopt the concept of super variant for the detection of genetic factors. A discovery-validation procedure is used for verifying the potential associations. Results We find 8 super variants that are consistently identified across multiple replications as susceptibility loci for COVID-19 mortality. The identified risk factors on chromosomes 2, 6, 7, 8, 10, 16, and 17 contain genetic variants and genes related to cilia dysfunctions ( DNAH7 and CLUAP1 ), cardiovascular diseases ( DES and SPEG ), thromboembolic disease ( STXBP5 ), mitochondrial dysfunctions ( TOMM7 ), and innate immune system ( WSB1 ). It is noteworthy that DNAH7 has been reported recently as the most downregulated gene after infecting human bronchial epithelial cells with SARS-CoV-2. Conclusions Eight genetic variants are identified to significantly increase the risk of COVID-19 mortality among the patients with white British ancestry. These findings may provide timely clues and potential directions for better understanding the molecular pathogenesis of COVID-19 and the genetic basis of heterogeneous susceptibility, with potential impact on new therapeutic options.